These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30483269)

  • 1. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
    Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
    Front Immunol; 2018; 9():2611. PubMed ID: 30483269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
    J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
    Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
    Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
    Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
    Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
    Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
    J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
    Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
    Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malaria-specific and nonspecific activation of CD8+ T cells during blood stage of Plasmodium berghei infection.
    Miyakoda M; Kimura D; Yuda M; Chinzei Y; Shibata Y; Honma K; Yui K
    J Immunol; 2008 Jul; 181(2):1420-8. PubMed ID: 18606696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection.
    Chibueze CE; Yoshimitsu M; Arima N
    Biochem Biophys Res Commun; 2014 Oct; 453(3):379-84. PubMed ID: 25277889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection.
    Wang Z; Yang H; Liu X; Zhang J; Han Z; Tao J; Zhao C; Ju X; Tan R; Gu M
    Med Sci Monit; 2018 Jan; 24():387-396. PubMed ID: 29352109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Basis of CD160:HVEM Recognition.
    Liu W; Garrett SC; Fedorov EV; Ramagopal UA; Garforth SJ; Bonanno JB; Almo SC
    Structure; 2019 Aug; 27(8):1286-1295.e4. PubMed ID: 31230945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT.
    Rodriguez-Barbosa JI; Schneider P; Weigert A; Lee KM; Kim TJ; Perez-Simon JA; Del Rio ML
    Cell Mol Immunol; 2019 Jul; 16(7):679-682. PubMed ID: 31160757
    [No Abstract]   [Full Text] [Related]  

  • 14. Expanded antigen-experienced CD160
    Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
    Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
    Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD160 expression on CD8
    Liu S; Zhang W; Liu K; Wang Y
    Cancer Immunol Immunother; 2020 May; 69(5):789-797. PubMed ID: 32055919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memory CD8
    Shaw TN; Haley MJ; Dookie RS; Godfrey JJ; Cheeseman AJ; Strangward P; Zeef LAH; Villegas-Mendez A; Couper KN
    Immunology; 2021 Dec; 164(4):737-753. PubMed ID: 34407221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
    Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
    PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria.
    Lepenies B; Pfeffer K; Hurchla MA; Murphy TL; Murphy KM; Oetzel J; Fleischer B; Jacobs T
    J Immunol; 2007 Sep; 179(6):4093-100. PubMed ID: 17785848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Angiotensin II Type-1 Receptor (AT
    Silva-Filho JL; Caruso-Neves C; Pinheiro AA
    Front Cell Infect Microbiol; 2017; 7():42. PubMed ID: 28261571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.